(주)셀렉스라이프사이언스

News

ILIAS is the Leader of Next-Generation Exosome Therapeutics.

[ENG] 보도자료

ILIAS Biologics Closes $20.6 Million Series B Financing

페이지 정보

  • 작성자 : ILIAS Biologics
  • 작성일 : 20-09-28 16:12
  • 조회 : 230회

본문

 

28 Sep 2020

 

ILIAS Biologics Closes $20.6 Million Series B Financing 

 

ILIAS Biologics Inc. has completed a Series B financing round of $20.6 million in South Korea. ILIAS has raised a total of $40.2 million of capital since its foundation in November 2015. This financing will support the continued development of ILIAS’s proprietary EXPLOR® platform technology and the advancement of exosome-based therapeutics pipeline.

 

The support from our new and existing investors is a reflection of their confidence in the immense potential of ILIAS’s exosome-based platform technology and the expertise of scientists and management teams at ILIAS. ILIAS will continue to work toward fulfilling our mission of transforming scientific imaginations into reality to advance human health.

 

Please find the link below for more information.

 

(Kor)

(Eng) 


개인정보취급방침

닫기

이메일주소무단수집거부

닫기

사이트맵

사이트맵

몬트리올의정서
국내이행법령
사업안내
특정물질 수출입
알림·자료실
민원서비스
닫기